A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

This study has been completed.

Sponsor:

Information provided by:

Pfizer

ClinicalTrials.gov Identifier:

NCT00990015

First received: October 2, 2009

Last updated: January 29, 2010

Last verified: January 2010

History of Changes

Purpose

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (understanding how a drug is absorbed and moves through the body) and pharmacodynamics (understanding the effects of a drug on certain target sites of activity in the body).

Condition	Intervention	Phase
Healthy Volunteers	Drug: PF-04308515 Drug: Placebo	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Basic Science
Official Title:	A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single-Dose Escalation Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04308515 in Healthy Volunteers

Further study details as provided by Pfizer:

Primary Outcome Measures:

To evaluate the safety, tolerability and pharmacokinetics (PK) of single-rising doses of PF-04308515 [ Time Frame: 1 day ]
To characterize the pharmacodynamic (PD) effects of PF-04308515 on biomarkers [ Time Frame: 1 day ]


Enrollment:	27
Study Start Date:	October 2009
Study Completion Date:	January 2010
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: PF-04308515	Drug: PF-04308515 Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
Placebo Comparator: Placebo	Drug: Placebo Placebo solution/suspension to match active drug QD at a single dose.

Eligibility


Ages Eligible for Study:	18 Years to 55 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy males between 18 and 55 years, inclusive
Healthy females between 18 and 44 years, inclusive.
Women need to be surgically sterile

Exclusion Criteria:

Evidence or history of clinically significant disease
Post-menopausal women
History of intolerance or significant adverse effects with glucocorticoids

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00990015

Locations


United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site


Responsible Party:	Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier:	NCT00990015 History of Changes
Other Study ID Numbers:	B0861001
Study First Received:	October 2, 2009
Last Updated:	January 29, 2010

Keywords provided by Pfizer:


Safety; tolerability; pharmacokinetics/pharmacodynamics

ClinicalTrials.gov processed this record on June 27, 2017

To Top